Ionis Pharmaceuticals Inc Rare Disease Webinar Series: Hereditary Angioedema Transcript
Good morning, everyone. Welcome. Thank you for joining us on this very first edition of the Ionis Rare Disease Webinar Series. I'm Kenneth Newman. I'm Vice President of Clinical Development and the Franchise Leader for the Pulmonary Immunology area here at Ionis.
Today, we'll be discussing hereditary angioedema, which is a debilitating and severe disease for which there are currently limited effective treatment options. I'm really honored and thrilled to have joining me today, Dr. Danny Cohn, who's an internist at the Amsterdam University Medical Center and the primary investigator for the Ionis PKK LICA program, and also 1 of the 2 global leaders in the diagnosis and treatment of HAE. Ionis antisense therapy is designed to target and treat the root cause of HAE. Danny?
Thank you very much for the kind introduction, Ken, and it's great to be here. I really look forward to have a very interesting discussion with you and, of course, also the patient who you are about to introduce and I also look forward to their questions from the audience.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |